ERBB2 and breast carcinoma: Immunotherapy based on monoclonal antibodies (mAb) targeting tumor-associated antigens (TAA) such as trastuzumab (anti-human epidermal growth factor receptor 2; HER2/neu) is clinically effective[1-6] and has thus become the standard of care for women with HER2/neu expressing breast cancer[7-9].